Hiroki Shiarasaki

  • Citations Per Year
Learn More
BACKGROUND The authors evaluate the efficacy and safety of gefitinib monotherapy in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). A secondary endpoint is to evaluate the relationship between clinical manifestations and epidermal growth factor receptor (EGFR) mutation status. METHODS Japanese chemotherapy-naive NSCLC(More)
  • 1